Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Revista Colombiana de Reumatología
Print version ISSN 0121-8123
Abstract
JAUREGUI, Edwin et al. Colombian Association of Rheumatology. Consensus on recommendations to decrease and discontinue biological therapy in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Rev.Colomb.Reumatol. [online]. 2019, vol.26, n.1, pp.11-23. ISSN 0121-8123. https://doi.org/10.1016/j.rcreue.2018.10.002.
Objective:
The objective of this study was to establish recommendations for the reduction and discontinuation of biological disease-modifying antirheumatic drugs, with the aim of becoming a guide document for health professionals involved in the management of patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
Materials and methods:
The recommendations were established through consensus by a panel of experts in rheumatology, and based on the analysis of available scientific evidence obtained from systematic reviews and the clinical experience of the panellists.
Results:
A total of 33 rheumatoid arthritis related studies were included, with 6 psoriatic arthritis related, and 9 ankylosing Spondylitis related. The recommendations for the reduction of biological therapies were made by establishing a plan to determine when and how to reduce the biological disease-modifying antirheumatic drugs in patients with these 3 diseases, and in some cases lead to the discontinuation of these treatments.
Conclusion:
The recommendations established in this document will serve as a guide to improve the efficiency of biological therapy in these diseases, reduce the variability in clinical practice, and establish an adequate risk/benefit ratio.
Keywords : Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; Biological drugs; Dose reduction; Biologic disease-modifying; antirheumatic drug; Conventional disease-modifying; antirheumatic drug..